Fermer X Les cookies sont necessaires au bon fonctionnement de 24hGold.com. En poursuivant votre navigation sur notre site, vous acceptez leur utilisation.
Pour en savoir plus sur les cookies...
AnglaisFrancais
Cours Or & Argent en

Myriad Genetics

Publié le 12 août 2015

Myriad Genetics Posts In-Line Earnings in Q4, Margins Suffer

( 0 vote, 0/5 ) Imprimer l'article
  Article Commentaires Commenter Notation Suivre la société  
0
envoyer
0
commenter

Myriad Genetics Posts In-Line Earnings in Q4, Margins Suffer

Myriad Genetics Inc. MYGN reported adjusted earnings per share (EPS) (considering acquisition-accelerated share-based compensation as a one-time item) of 41 cents in the fourth quarter of fiscal 2015, down 14.6% from the year-ago figure of 48 cents. Earnings were, however, in line with the Zacks Consensus Estimate.

The year-over-year deterioration in adjusted EPS was primarily due to lower gross and operating margins on account of the transition cost associated with the conversion to myRisk and increased product launch costs.

For fiscal 2015, Myriad reported adjusted EPS of $1.45, down 38% from $2.34 in fiscal 2014 and short of the Zacks Consensus Estimate by a penny.

Revenues

In the fourth quarter, total revenue rose 0.6% year over year to $189.9 million, exceeding the company’s guidance of $187 to $189 million. The top line beat the Zacks Consensus Estimate of $188 million by a whisker.

Although total revenue dropped 7.1% to $723.1 million in fiscal 2015, it surpassed the company’s guidance of $720–$722 million as well as the Zacks Consensus Estimate of $720 million.

Revenue growth in the fourth quarter was primarily driven by robust double-digit growth in pharmaceutical and clinical services revenue.

In the reported quarter, Myriad's Molecular diagnostic tests (94.2% of total revenue) recorded total revenue of $178.8 million, down 2.2% year over year primarily derived from sluggish Hereditary cancer testing revenues (down 3% at $163.8 million) and Vectra DA testing revenues (up 9% at $11.8 million). 

Pharmaceutical and clinical service revenues (accounting for the rest) in the fourth quarter grossed $11.1 million, up a solid 88% year over year.

Revenues from Myriad's myRisk Hereditary Cancer surged a massive 269.6% to $100.9 million from the year-ago equivalent of $27.3 million. In the reported quarter, myRisk conversion increased to 52% of incoming hereditary cancer samples. In fact, myRisk comprised 62% of total hereditary cancer revenue in the quarter.

Margin Trends

Adjusted gross margin during the quarter contracted 330 basis points (bps) to 80.3%, primarily weighed down by the transition cost associated with converting Myriad’s single cancer syndrome test to myRisk Hereditary Cancer testing and incremental product launch expenses for Prolaris, myPath Melanoma and myPlan Lung Cancer tests.

Adjusted operating expenses spiked 2.7% to $104.2 million due to a 5.3% increase in adjusted selling, general and administrative expenses (to $85.7 million). However, research and development expenses declined 8% (to $16 million) in the fourth quarter.

As a result, adjusted operating margin contracted 440 bps year over year to 25.4% in the quarter, on account of higher investments across Myriad’s portfolio of products and some decline in profits associated with the transition to myRisk in the Hereditary Cancer franchise.

Financial Position

Myriad exited fiscal 2015 with cash, cash equivalents and marketable securities of $144.8 million, down from $186.4 million as of Jun 30, 2014. In fiscal 2015, Myriad reported cash flow from operations of $140.5 million, down 26.1% from the year-ago equivalent of $190.2 million. Consequently, free cash flow from operations was $116.6 million, as against $175.9 million in fiscal 2014.

The company repurchased 1.3 million shares for $45 million during the quarter and was left with an authorization to buy back stock worth another $155 million.

Guidance

Myriad has provided its guidance for fiscal 2016. The company envisages revenues in the range of $750–$770 million, with annualized growth of 4–6%. The Zacks Consensus Estimate of $749 million lies below this guidance.

On the other hand, the company expects adjusted EPS for fiscal 2016 in the range of $1.60–$1.65, reflecting annualized growth of 10–13%. The current Zacks Consensus Estimate of $1.73 lies way above Myriad's guidance.

Management has also provided its outlook for first-quarter fiscal 2016. The company expects adjusted earnings per share of 34–36 cents on total revenue of $176–$178 million. The Zacks Consensus Estimate of adjusted EPS of 40 cents and revenues of $189 million lie above the respective guidance ranges.

Our View

Myriad ended fourth-quarter fiscal 2015 on a more or less satisfactory note as its bottom line met our estimate and the top line closely beat the same. On an encouraging note, Myriad successfully returned to positive top-line growth in the fourth quarter, after witnessing substantial declines in its revenue numbers consecutively since the beginning of fiscal 2015. Going forward, Myriad expects to deliver positive year-over-year revenue growth in each quarter of fiscal 2016. This further bolsters our confidence in the stock.

However, from the profitability standpoint, we are disappointed with the company’s weak gross margin performance in the fourth quarter. As long as Myriad does not receive reimbursement coverage for its new tests, such as myPath melanoma and Prolaris, increased launch costs for these tests will continue to weigh heavily on Myriad’s gross margin. Nevertheless, on a positive note, management currently expects gross margin improvement in fiscal 2016 based upon increased efficiencies in the myRisk laboratory and Medicare reimbursement for Prolaris, which should be in place by Oct 2015.

Moreover, the huge contraction that Myriad witnessed in its operating margin figure also disappoints us. However it is a relief to note that the company expects to generate significant operating leverage in fiscal 2016, wherein it expects to witness a 200 basis points improvement in the operating margin figure.

Zacks Rank

Currently, Myriad carries a Zacks Rank #3 (Hold). Better-ranked med-biomed/generic stocks include AMAG Pharmaceuticals, Inc. AMAG, Gilead Sciences Inc. GILD and Neogenomics Inc. NEO. All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GILEAD SCIENCES (GILD): Free Stock Analysis Report
 
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
 
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
 
NEOGENOMICS INC (NEO): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research
Lire la suite de l'article sur finance.yahoo.com

CODE :
Suivi et investissement
Add to watch list Add to your portfolio Add or edit a note
Ajouter une alerte Ajouter aux Watchlists Ajouter au portefeuille Ajouter une note
ProfilIndicateurs
de Marché
VALEUR :
Projets & res.
Communiqués
de Presse
Rapport
annuel
RISQUE :
Profile actifs
Contactez la cie

Myriad Genetics est une société basée aux Etats-Unis D'Amerique.

Myriad Genetics est cotée aux Etats-Unis D'Amerique. Sa capitalisation boursière aujourd'hui est 1,7 milliards US$ (1,6 milliards €).

La valeur de son action a atteint son plus bas niveau récent le 29 mai 1998 à 10,00 US$, et son plus haut niveau récent le 17 novembre 2000 à 94,06 US$.

Myriad Genetics possède 68 090 000 actions en circulation.

Votre avis nous interesse, merci de laisser un commentaire ou de noter cet article.
Evaluer : Note moyenne :0 (0 vote) Voir les mieux notés
 
Communiqués de Presse de
27/01/2016Will Myriad Genetics Q2 Earnings (MYGN) Surprise Investors?
31/12/2015Myriad Genetics Trades above Its 100-Day Moving Average
29/12/201510 Biotechs Short Sellers Are Betting Against
22/12/2015Myriad Genetics: Test Expansion Strong, Currency Woes Linger
08/12/2015Top Analyst Upgrades and Downgrades: Amazon, Blackstone, Fir...
02/12/2015What Do Hedge Funds Think of World Fuel Services Corporation...
27/11/2015Is Myriad Genetics, Inc. (MYGN) A Good Stock To Buy?
04/11/2015Edited Transcript of MYGN earnings conference call or presen...
03/11/2015Myriad Genetics (MYGN) Q1 FY16 Earnings: Beats On Earnings a...
03/11/2015Myriad Genetics Reports Fiscal First-Quarter 2016 Financial ...
03/11/2015Myriad beats Street 1Q forecasts
03/11/20154:22 pm Myriad Genetics beats by $0.06, beats on revs; guide...
02/11/2015Is Myriad Genetics (MYGN) Poised to Beat on Q1 Earnings?
02/11/2015PDF 12.39 KB
28/10/2015Myriad Genetics to Present at the 2015 Credit Suisse Healthc...
22/10/2015Crescendo Bioscience Highlights New Studies With Vectra(R) D...
20/10/2015Myriad to Announce Fiscal First Quarter 2016 Financial Resul...
14/10/2015Grifols and Myriad Traded above the 100-Day Moving Averages
12/10/2015Gamestop, Neustar, Myriad among most shorted in late Septemb...
09/10/2015Myriad to Present New Data on Its myRisk(TM) Hereditary Canc...
08/10/2015Myriad Genetics to Highlight New Clinical Outcomes Data on m...
07/10/2015Myriad Genetics and Tufts Health Plan Sign Agreement to Cove...
05/10/2015Myriad to Present Seven Studies at the ASHG Annual Meeting
01/10/2015Myriad Appoints Jan Schluchter as Chief Commercial Officer f...
30/09/2015XBI’s Moving Averages: The Massive Plummet Last Week
25/09/2015Myriad Genetics Posts Positive Data on Oncology Tests
24/09/2015Myriad Genetics: Study Results Impress, Currency Woes Stay
24/09/20157:09 am Myriad Genetics to present new studies on the myChoi...
17/09/2015Performance of XBI and IBB with Respective Benchmark Indexes
14/09/2015Myriad Genetics to Present at the 2015 Morgan Stanley Health...
11/09/2015Myriad Genetics, Inc. (Nasdaq: MYGN) to Ring The Nasdaq Stoc...
09/09/2015Myriad Adds to Scientific Evidence for the myPlan(R) Lung Ca...
02/09/2015Myriad Genetics to Host 2015 Investor Day in New York City
01/09/2015Crescendo Bioscience Names Elena Hitraya M.D., Ph.D., as Chi...
31/08/2015New guidelines for cancer doctors aim to make sense of gene ...
18/08/2015Myriad Genetics: myRisk Offers Strength, Currency Woes Linge...
15/08/201510-K for Myriad Genetics, Inc.
14/08/2015Myriad: Medicare Coverage for Prolaris Prostrate Cancer Test
13/08/2015Myriad Genetics (MYGN) Jumps: Stock Moves 6.8% Higher
13/08/2015Myriad Receives Favorable Medicare Final Coverage Decision f...
12/08/2015Myriad Genetics Posts In-Line Earnings in Q4, Margins Suffer
12/08/2015Edited Transcript of MYGN earnings conference call or presen...
11/08/2015Myriad meets 4Q profit forecasts
11/08/2015Myriad Genetics Reports Fiscal Fourth-Quarter and Full Year ...
11/08/20154:07 pm Myriad Genetics reports EPS in-line, beats on revs; ...
10/08/2015Fossil Group, Myriad Genetics Among The Earnings Reports To ...
10/08/2015PDF 12.06 KB
03/08/2015Will Health Net (HNT) Earnings Pull a Surprise This Season? ...
24/06/2015Chris4Life and Myriad Launch "What's Your History" Week and ...
15/06/201510 Movers To Keep An Eye On This Monday
31/05/20157:00 am Myriad Genetics announces new clinical studies on it...
09/05/201510-Q for Myriad Genetics, Inc.
21/04/2015Color Genomics Sells $249 Breast Cancer Gene Test to Masses
21/04/2015Quest Diagnostics, French agency seek to expand breast cance...
01/04/2015Myriad and AstraZeneca Expand Research Collaboration on Lynp...
01/04/20157:08 am Myriad Genetics announces the expansion of its compa...
26/03/2015Goldman Sachs Cuts Myriad Genetics To Sell, Ups Alere
23/03/2015Myriad Poised on Portfolio Strength Despite Y/Y Downfall in ...
20/03/2015Myriad Announces Prolaris(R) Test Biopsy Results From EMPATH...
17/03/2015Myriad and BioMarin Expand Collaboration to Evaluate myChoic...
09/03/2015Myriad Genetics Unveils Simoa-based Immunoassay Services - A...
05/03/2015Myriad RBM Launches New Immunoassay Services Based on the Ul...
04/03/2015Myriad Publishes myPath(TM) Melanoma Pivotal Validation Stud...
03/03/2015Myriad Genetics to Present at the Barclays Global Healthcare...
02/03/2015Myriad Genetics to Present at the Barclays Global Healthcare...
02/03/2015What Falling Estimates & Price Mean for Myriad Genetics (MYG...
25/02/2015Heavy News Day For Several Biotech Stocks
25/02/2015Myriad Board Approves $200 Million Increase in Share Repurch...
17/02/2015Iridian bumps up position in Myriad Genetics
17/02/2015GeneDx, Inc. and its Parent BioReference Labs Announce Settl...
09/02/2015Quest Diagnostics and Myriad Genetics End BRCA Patent Litiga...
06/02/2015Myriad Genetics to Present at the 2015 Leerink Global Health...
04/02/2015JMP Securities Upgrades Myriad Genetics, Says 'Revised Guida...
04/02/2015Ahead of the Bell: Myriad sinks after cutting 2015 forecast
03/02/2015Myriad beats Street 2Q forecasts
02/02/2015PDF 11.70 KB
22/01/2015Myriad Genetics Names Johnathan M. Lancaster as Vice Preside...
20/01/2015Myriad RBM Joins Institut Pasteur in the Global Fight Agains...
08/01/2015Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and La...
19/12/2014Myriad Receives FDA Approval of BRACAnalysis CDx(TM) as Comp...
09/12/2014Three New Myriad Studies Highlighted at 2014 San Antonio Bre...
03/12/2014Myriad to Present Eight Studies at 2014 San Antonio Breast C...
02/12/2014Study Shows Prolaris(R) Could Save Healthcare System $6 Bill...
20/11/2014TESARO and Myriad Announce Companion Diagnostics Collaborati...
04/11/2014Myriad misses Street 1Q forecasts
Publication de commentaires terminée
 
Dernier commentaire publié pour cet article
Soyez le premier à donner votre avis
Ajouter votre commentaire
NASDAQ (MYGN)
25,00-1.44%
US$ 25,00
15/05 16:17 -0,360
-1,44%
Cours préc. Ouverture
25,36 25,60
Bas haut
24,83 25,65
Année b/h Var. YTD
17,59 -  25,47 31,58%
52 sem. b/h var. 52 sem.
13,91 -  25,47 32,84%
Volume var. 1 mois
931 426 30,41%
Produit
Développe
Recherche
 
 
 
Analyse
Interactive chart Add to compare
Graphique
interactif
Imprimer Comparer Exporter
Vous devez être connecté pour accéder au portefeuille (gratuit)
Top Newsreleases
LES PLUS LUS
Variation annuelle
DateVariationMaxiMini
202430,59%23,7517,18
202331,91%24,2113,82
2022-46,66%28,1913,92
202137,57%36,9619,50
2020-26,16%30,1210,54
 
Graphique 5 ans
 
Graphique 3 mois
 
Graphique volume 3 mois
 
 
Nouvelles des Sociétés Minières
Plymouth Minerals LTDPLH.AX
Plymouth Minerals Intersects Further High Grade Potash in Drilling at Banio Potash Project - Plannin
0,12 AU$-8,00%Trend Power :
Santos(Ngas-Oil)STO.AX
announces expected non-cash impairment
7,72 AU$-0,19%Trend Power :
OceanaGold(Au)OGC.AX
RELEASES NEW TECHNICAL REPORT FOR THE HAILE GOLD MINE
2,20 AU$+0,00%Trend Power :
Western Areas NL(Au-Ni-Pl)WSA.AX
Advance Notice - Full Year Results Conference Call
3,86 AU$+0,00%Trend Power :
Canadian Zinc(Ag-Au-Cu)CZN.TO
Reports Financial Results for Q2 and Provides Project Updates
0,12 CA$+4,55%Trend Power :
Stornoway Diamond(Gems-Au-Ur)SWY.TO
Second Quarter Results
0,02 CA$+100,00%Trend Power :
McEwen Mining(Cu-Le-Zn)MUX
TO ACQUIRE BLACK FOX FROM PRIMERO=C2=A0
10,76 US$+0,56%Trend Power :
Rentech(Coal-Ngas)RTK
Rentech Announces Results for Second Quarter 2017
0,20 US$-12,28%Trend Power :
KEFIKEFI.L
Reduced Funding Requirement
0,73 GBX+1,39%Trend Power :
Lupaka Gold Corp.LPK.V
Lupaka Gold Receives First Tranche Under Amended Invicta Financing Agreement
0,05 CA$-9,09%Trend Power :
Imperial(Ag-Au-Cu)III.TO
Closes Bridge Loan Financing
2,63 CA$-0,38%Trend Power :
Guyana Goldfields(Cu-Zn-Pa)GUY.TO
Reports Second Quarter 2017 Results and Maintains Production Guidance
1,84 CA$+0,00%Trend Power :
Lundin Mining(Ag-Au-Cu)LUN.TO
d Share Capital and Voting Rights for Lundin Mining
16,85 CA$-0,82%Trend Power :
Canarc Res.(Au)CCM.TO
Canarc Reports High Grade Gold in Surface Rock Samples at Fondaway Canyon, Nevada
0,24 CA$+0,00%Trend Power :
Havilah(Cu-Le-Zn)HAV.AX
Q A April 2017 Quarterly Report
0,22 AU$+7,50%Trend Power :
Uranium Res.(Ur)URRE
Commences Lithium Exploration Drilling at the Columbus Basin Project
6,80 US$-2,86%Trend Power :
Platinum Group Metals(Au-Cu-Gems)PTM.TO
Platinum Group Metals Ltd. Operational and Strategic Process ...
2,25 CA$+13,64%Trend Power :
Devon Energy(Ngas-Oil)DVN
Announces $340 Million of Non-Core Asset Sales
49,34 US$-0,99%Trend Power :
Precision Drilling(Oil)PD-UN.TO
Announces 2017Second Quarter Financial Results
8,66 CA$-0,35%Trend Power :
Terramin(Ag-Au-Cu)TZN.AX
2nd Quarter Report
0,04 AU$+0,00%Trend Power :